Projects

Collaborative vaccine R&D Projects

LiteVax Adjuvant is a versatile adjuvant technology developed to improve prophylactic vaccines. Our programs are collaborations with private and public partners active in vaccine development and focus on proof of concept in relevant models and early clinical phase.

Project

Therapeutic area

Discovery

Preclinical

Toxicology

CTA ready

Phase I

Phase II

INDIGO
(H2020)

Adjuvanted
seasonal
influenza
vaccine (EU)

NCT05581407
NCT06294262

INDIGO
(H2020)

Adjuvanted
seasonal
influenza
vaccine (India)

INDIGO
(H2020)

Adjuvanted
pandemic
influenza
vaccine

PCV-LITE
(in-house)

Adjuvanted
conjugated
pneumococcal
vaccine

BACTOVAC
(EUROSTARS)

Adjuvanted
C. difficile
vaccine

UTOPIA
(EUROSTARS)

Adjuvanted
UTI
E.coli
vaccine

INDIGO; Development of a better and/or affordable seasonal influenza vaccine for the globe. A consortium of public and private R&D organisations from EU, India, and US. Granted by EU (Horizon 2020) and Department of Biotechnology of India. The project largely builds on LiteVax’s proprietary technology.

PCV-LITE; Development of a non-inferior fractional-dose pneumococcal conjugate vaccine (PCV) concept.

In a recent preclinical study (see figure), 1/5th of PCV plus LiteVax Adjuvant gave similar or even higher responses than the standard dose of PCV.

BACTOVAC; Development of a vaccine targeting Clostridium difficile infection in collaboration with Proxi Biotech (DE). Sponsored by EUROSTARS and TRANSVAC2

UTOPIA;. Development of a vaccine targeting Urinary Tract Infections in collaboration with GlyProVac (DE), Spectralys (BE) and Odense University Hospital (DE). Sponsored by EUROSTARS.